Cagrilintide
A long-acting amylin analog under investigation for obesity, both as monotherapy and in fixed combination with semaglutide (CagriSema). Amylin is a satiety hormone co-secreted with insulin by pancreatic beta cells.
Tirzepatide
A first-in-class dual agonist of the GIP and GLP-1 receptors, approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. Its dual mechanism delivers some of the largest weight reductions reported in registrational obesity trials.
Mechanism
Tirzepatide is a single peptide activating both GLP-1 and GIP receptors. CagriSema combines semaglutide (selective GLP-1 agonism) with cagrilintide, a long-acting amylin analog adding satiety and glucagon-related effects through a completely separate receptor system. Different architectures aimed at the same clinical target.
Trial results
Tirzepatide’s SURMOUNT-1 reported 20.9% mean weight reduction at the highest dose over 72 weeks. CagriSema’s REDEFINE-1 reported roughly 22.7% at week 72 — with the important caveat that these are cross-trial numbers from different populations and designs. Head-to-head data do not yet exist.
Status
Tirzepatide is approved for type 2 diabetes and chronic weight management. CagriSema is in late-stage development; regulatory submissions are underway but approval is not granted until it is granted.
Safety
Both approaches are dominated by gastrointestinal effects. CagriSema adds amylin-class considerations and dose-titration complexity from co-formulation. Long-term data for the combination are necessarily shorter than tirzepatide’s.
Practical difference
One is an approved medicine with a defined label; the other is a registrational-stage candidate. Any gray-market version of either is outside every quality system that makes the real versions meaningful.
Frequently Asked Questions
Is CagriSema stronger than tirzepatide?
Cross-trial averages are not the right tool for that comparison. REDEFINE-1 and SURMOUNT-1 studied different populations; no head-to-head trial has reported yet.
Why combine amylin with GLP-1?
Because they act at different receptors with complementary satiety effects — a plausible pharmacological rationale that trials are now testing, not a marketing invention.
Can either be sourced as a research chemical?
Both appear on gray markets, and both are exactly the kind of compound where unverified identity is most dangerous — large molecules, sensitive formulations, and potent metabolic effects.
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.